Eli Lilly to acquire Centessa Pharmaceuticals for $6.3B

Pharmaceutical giant Eli Lilly has announced an agreement to acquire Centessa Pharmaceuticals for an initial sum of approximately $6.3 billion. This strategic acquisition is set to bolster Eli Lilly's presence in the neuroscience sector. The deal specifically enhances the company's capabilities in sleep medicine research and development. Centessa Pharmaceuticals brings a portfolio of clinical-stage assets that align with Eli Lilly's growth objectives.